Literature DB >> 11570901

Nongynecologic cytology turnaround time: a College of American Pathologists Q-Probes study of 180 laboratories.

B A Jones1, D A Novis.   

Abstract

OBJECTIVES: To determine the turnaround time for nongynecologic cytology and to identify laboratory and specimen characteristics associated with variations in turnaround time. DESIGN AND
SETTING: Prospective evaluation of nongynecologic cytology turnaround times in 180 laboratories. MAIN OUTCOME MEASURE: Nongynecologic cytology case turnaround time.
RESULTS: Participants from 180 laboratories submitted turnaround times for 16 950 nongynecologic cytology cases and submitted information describing their laboratories' practice characteristics relating to the processing of nongynecologic cytology specimens. Half of the participating laboratories had mean receipt to report turnaround times of 1.6 calendar days or less and were able to complete 90% of their cases within 3.0 calendar days. Ten percent of participants had mean turnaround times greater than 3.2 days and required 6.0 or more days to report 90% of their cases. Longer turnaround times were associated with processing fluid and fine-needle aspiration specimens, issuing atypical/suspicious for malignancy and nondiagnostic diagnoses, having cytotechnologist students screen slides, having to contact the physician offices for additional information, having to retrieve prior case material for review, and having to perform cell blocks and/or special stains.
CONCLUSION: There is an opportunity for laboratories to shorten nongynecologic turnaround time by altering certain laboratory practices.

Entities:  

Mesh:

Year:  2001        PMID: 11570901     DOI: 10.5858/2001-125-1279-NCTT

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  1 in total

Review 1.  Mapping turnaround times (TAT) to a generic timeline: a systematic review of TAT definitions in clinical domains.

Authors:  Bernhard Breil; Fleur Fritz; Volker Thiemann; Martin Dugas
Journal:  BMC Med Inform Decis Mak       Date:  2011-05-24       Impact factor: 2.796

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.